Generation of human iPSCs from fetal prostate fibroblasts HPrF

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F19%3A00072539" target="_blank" >RIV/00159816:_____/19:00072539 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1016/j.scr.2019.101405" target="_blank" >http://dx.doi.org/10.1016/j.scr.2019.101405</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.scr.2019.101405" target="_blank" >10.1016/j.scr.2019.101405</a>

Result language

angličtina

Original language name

Generation of human iPSCs from fetal prostate fibroblasts HPrF

Original language description

Human induced pluripotent stem cell line was generated from commercially available primary human prostate fibroblasts HPrF derived from a fetus, aged 18-24 weeks of gestation. The fibroblast cell line was reprogrammed with Yamanaka factors (OCT4, SOX2, c-MYC, KLF4) using CytoTune (TM)-iPS 2.0 Sendai Reprogramming Kit. Pluripotency of the derived transgene-free iPS cell line was confirmed both in vitro by detecting the expression of factors of pluripotency on a single-cell level, and in vivo using teratoma formation assay. This iPS cell line will be a useful tool for studying both normal prostate development and prostate cancer disease.

Czech name

—

Czech description

—

Type

O - Miscellaneous

CEP classification

—

OECD FORD branch

20602 - Medical laboratory technology (including laboratory samples analysis; diagnostic technologies) (Biomaterials to be 2.9 [physical characteristics of living material as related to medical implants, devices, sensors])

Project

<a href="/en/project/LQ1605" target="_blank" >LQ1605: Translational Medicine</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů